Accurate PD-L1 Protocols for Non-Small Cell Lung Cancer can be Developed for Automated Staining Platforms with Clone 22C3

Applied Immunohistochemistry and Molecular Morphology

Volumn 25, Issue 6, 2017, Pages 381-385

  Røge, Rasmus ^a   Vyberg, Mogens ^a   Nielsen, Søren ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

immunohistochemistry; PD L1; standardization

Indexed keywords

PEMBROLIZUMAB; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

ADENOCARCINOMA; ANTIBODY TITER; ARTICLE; HUMAN; IMAGE ANALYSIS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; TISSUE MICROARRAY; AUTOMATION; LUNG TUMOR; METABOLISM;

AUTOMATION; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS;

EID: 85024373495     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000534     Document Type: Article

References (2)

1. Hirsch FR, McElhinny A, Stanforth D,. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017; 12: 208-222.
2. Scheel AH, Dietel M, Heukamp LC,. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 2016; 29: 1165-1172.